Literature DB >> 8258339

Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells.

M Battegay1, D Kyburz, H Hengartner, R M Zinkernagel.   

Abstract

The effects of neutralizing antibodies on the disease course in mice infected with the noncytopathic lymphocytic choriomeningitis virus (LCMV) were evaluated. Whereas non-neutralizing antisera exhibiting high enzyme-linked immunosorbent assay titers had no effect on T cell responses and their consequences, neutralizing antisera modulated them variably. Neutralizing antibodies were able to prevent lethal choriomeningitis after intracerebral infection with a neurotropic LCMV-isolate (ARMSTRONG) although they could not control local virus replication. The same antibodies exhibited little or no protective effect on choriomeningitis induced by LCMV-WE, a viscerotrope isolate. Surprisingly, these antibodies rendered mice much more susceptible to choriomeningitis after intracerebral infection with LCMV DOCILE, a very rapidly spreading lymphocyto-viscerotrope virus; in this situation antibodies prevented overwhelming infection which causes deletion of immunopathogenic cytotoxic T cell responses. Thus preexisting neutralizing antiviral antibodies had little influence on local virus spread in peripheral tissues but they reduced hematogenic spread and infection of antigen-presenting cells; thereby they influenced the primary cytotoxic T cell (CTL) response and indirectly modulated the extent of T cell-mediated immunopathology in peripheral organs. These results may explain why vaccines inducing neutralizing antibodies but no CTL may enhance an immunopathological disease caused by challenge infection with a noncytopathic virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258339     DOI: 10.1002/eji.1830231229

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Authors:  P Seiler; B M Senn; P Klenerman; U Kalinke; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice.

Authors:  P Seiler; U Kalinke; T Rülicke; E M Bucher; C Böse; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 4.  Host factors influencing viral persistence.

Authors:  A R Thomsen; A Nansen; S O Andreasen; D Wodarz; J P Christensen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-08-29       Impact factor: 6.237

5.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Specific T-cell response correlates with resistance of genetic heterogeneous mouse populations to mouse hepatitis virus 3 infection.

Authors:  R C Vassão; W H Cabrera; O C Ibanez; C A Pereira
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

7.  Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction.

Authors:  M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

8.  Immunogenicity of a viral model vaccine after different inactivation procedures.

Authors:  M F Bachmann; C Bast; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

9.  Suppression of measles virus expression by noncytolytic antibody in an immortalized macrophage cell line.

Authors:  M B Goldman; T A O'Bryan; D J Buckthal; L M Tetor; J N Goldman
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.

Authors:  M Battegay; D Moskophidis; A Rahemtulla; H Hengartner; T W Mak; R M Zinkernagel
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.